Organ-specific immune-related adverse events and prognosis in cancer patients receiving immune checkpoint inhibitors.

ABSTRACT:

Background

Patients who developed immune-related adverse events (irAEs) could benefit more from treatment with immune checkpoint inhibitors (ICIs) than those who did not develop irAEs. This study was designed to assess whether the occurrence of irAEs or their characteristics are correlated with survival in advanced patients treated with ICIs.

Methods

This retrospective cohort study enrolled a panel of cancer patients who received ICIs at a single institute. Kaplan‒Meier curves were generated to describe progression-free survival (PFS) and overall survival (OS) in patients with irAEs or specific irAE characteristics.

Results

A total of 238 patients were enrolled, 83 (34.9%) of whom developed at least one irAE. Overall, irAE development was associated with prolonged OS

SUBMITTER: Han X 

PROVIDER: S-EPMC11761211 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature